(EVOK) Evoke Pharma - Performance -27.5% in 12m
EVOK performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-88.96%
#185 in Peer-Group
Rel. Strength
23.81%
#5856 in Stock-Universe
Total Return 12m
-27.54%
#125 in Peer-Group
Total Return 5y
-99.07%
#191 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 7.08 USD |
| 52 Week Low | 2.07 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 94.00 |
| Buy/Sell Signal +-5 | -1.61 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: EVOK (-27.5%) vs XLV (-8.7%)
5y Drawdown (Underwater) Chart
Top Performer in Pharmaceuticals
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| CORT NASDAQ Corcept Therapeutics |
0.72% | 121% | 333% | 62.6 | 55.3 | 0.61 | 23.7% | -5.15% |
| NVS NYSE Novartis |
1.34% | 12.4% | 75.7% | 19.4 | 14.7 | 1.44 | 8.70% | 9.2% |
| LLY NYSE Eli Lilly |
-4.44% | -18.3% | 393% | 64.5 | 36.4 | 1.21 | 58.2% | 18.9% |
| NOVN SW Novartis |
0.06% | 0.79% | 50.7% | 19.5 | 14.7 | 1.44 | 8.70% | 9.2% |
| GSK NYSE GlaxoSmithKline |
-6.59% | 2.11% | 42.2% | 19.1 | 8.73 | 0.38 | -25.2% | 3.11% |
| SFZN SW Siegfried Holding |
-4.81% | -9.99% | 101% | 24.2 | 23.6 | 1.48 | -42.4% | -29.3% |
| IPN PA Ipsen |
2.02% | -3.39% | 42.9% | 25.8 | 10.4 | 0.74 | -6.40% | -6.33% |
| UCB BR UCB |
6.55% | 20.8% | 61.9% | 31.1 | 22 | 1.04 | -22.4% | 39.5% |
Performance Comparison: EVOK vs XLV vs S&P 500
XLV (Health Care Sector SPDR ETF) is the Sector Benchmark for EVOK
| Total Return (including Dividends) | EVOK | XLV | S&P 500 |
|---|---|---|---|
| 1 Month | 74.23% | -1.83% | 3.54% |
| 3 Months | 144.29% | -3.24% | 16.07% |
| 12 Months | -27.54% | -8.73% | 12.18% |
| 5 Years | -99.07% | 35.53% | 107.69% |
| Trend Score (consistency of price movement) | EVOK | XLV | S&P 500 |
|---|---|---|---|
| 1 Month | 11.2% | 35.5% | 91.4% |
| 3 Months | 30.3% | -14.5% | 97.5% |
| 12 Months | -69.7% | -79.5% | 46.7% |
| 5 Years | -98.7% | 87.6% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XLV | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th98.00 | 77.47% | 68.28% |
| 3 Month | %th97.50 | 152.46% | 110.47% |
| 12 Month | %th38.00 | -20.61% | -35.41% |
| 5 Years | %th6.00 | -99.31% | -99.55% |
FAQs
Does Evoke Pharma (EVOK) outperform the market?
No,
over the last 12 months EVOK made -27.54%, while its related Sector, the Health Care Sector SPDR (XLV) made -8.73%.
Over the last 3 months EVOK made 144.29%, while XLV made -3.24%.
Performance Comparison EVOK vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
EVOK vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 92.6% | 70.7% | 8.2% | -40% |
| US NASDAQ 100 | QQQ | 92.1% | 69.9% | 5.7% | -40% |
| German DAX 40 | DAX | 92.5% | 72.3% | -4.9% | -57% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 92% | 69.3% | 4.2% | -47% |
| Hongkong Hang Seng | HSI | 92% | 71.8% | -13.8% | -62% |
| India NIFTY 50 | INDA | 94.3% | 73.7% | 6.7% | -24% |
| Brasil Bovespa | EWZ | 97.2% | 77.2% | -3.9% | -28% |
EVOK vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 93.6% | 72.4% | 4% | -51% |
| Consumer Discretionary | XLY | 92.2% | 71.7% | 16.9% | -43% |
| Consumer Staples | XLP | 94.4% | 75% | 7.4% | -34% |
| Energy | XLE | 94.7% | 74.5% | 18.4% | -25% |
| Financial | XLF | 93.9% | 71.7% | 8.6% | -49% |
| Health Care | XLV | 94.6% | 76.1% | 18.6% | -19% |
| Industrial | XLI | 92.2% | 69.6% | 2.3% | -49% |
| Materials | XLB | 95.2% | 72.6% | 10.3% | -28% |
| Real Estate | XLRE | 93.1% | 74.8% | 9.4% | -34% |
| Technology | XLK | 92.2% | 67.9% | 2.3% | -38% |
| Utilities | XLU | 91.8% | 72.3% | 5.5% | -49% |
| Aerospace & Defense | XAR | 89.7% | 65% | -12.4% | -76% |
| Biotech | XBI | 91.4% | 71.2% | 16.7% | -14% |
| Homebuilder | XHB | 94.3% | 68.7% | 21.5% | -21% |
| Retail | XRT | 93.8% | 71.4% | 12.3% | -32% |
EVOK vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 95.1% | 78.5% | 24.5% | -21% |
| Natural Gas | UNG | 88.1% | 82.7% | 32.5% | -35% |
| Gold | GLD | 92% | 75.9% | -9.5% | -65% |
| Silver | SLV | 90% | 70.5% | -8.8% | -50% |
| Copper | CPER | 91.3% | 60.6% | -10.6% | -50% |
EVOK vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 94.1% | 74.4% | 13.7% | -23% |
| iShares High Yield Corp. Bond | HYG | 93% | 73.3% | 10.1% | -36% |